Developing Scientifically Robust “Surrogate” Endpoints Aligned with Regulatory Expectations to Enhance Clinical Trial Execution
Time: 8:45 am
day: Day Two
Details:
• Current efforts to generate the level of evidence necessary to elevate ctDNA modulation as “surrogate” endpoint
• Leveraging liquid biopsies to guide dosage
• How to adapt to the changing regulatory environment to integrate new, ctDNA-based, “surrogate” endpoints into clinical trials?